Compare · LTGO vs NVS
LTGO vs NVS
Side-by-side comparison of Latigo Biotherapeutics Inc. (LTGO) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LTGO and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $306.26B, about 352.4x LTGO ($869.2M).
- LTGO has been more active in the news (7 items in the past 4 weeks vs 5 for NVS).
- NVS has more recent analyst coverage (25 ratings vs 0 for LTGO).
- Company
- Latigo Biotherapeutics Inc.
- Novartis AG
- Price
- -
- $162.01+0.92%
- Market cap
- $869.2M
- $306.26B
- 1M return
- -
- +6.79%
- 1Y return
- -
- +22.07%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2026
- News (4w)
- 7
- 5
- Recent ratings
- 0
- 25
Latigo Biotherapeutics Inc.
Latigo Biotherapeutics is a private clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction, with the goal to provide effective, rapid-acting pain relief. Latigo is supported by leading investors, including Westlake Village BioPartners, Foresite Capital, 5AM Ventures, and Blue Owl Capital. Latigo's lead program is LTG-001, an oral, selective Nav1.8 inhibitor in development to treat acute pain.
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest LTGO
- SEC Form SCHEDULE 13G filed by Latigo Biotherapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Latigo Biotherapeutics Inc.
- SEC Form 10-Q filed by Latigo Biotherapeutics Inc.
- Latigo Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits
- Latigo Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
- Latigo Biotherapeutics Announces CEO Transition to Support the Company’s Next Phase of Growth
- Latigo Biotherapeutics to Participate in Upcoming Investor Conferences in November
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form FWP filed by Novartis AG
- FDA Approval for LAMPRENE issued to NOVARTIS
- Novartis AG downgraded by Deutsche Bank
- SEC Form 6-K filed by Novartis AG
- Big Pharma Setbacks Create a New Wave of Rebound Plays
- Novartis AG upgraded by HSBC Securities
- Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
- RBC Capital Mkts initiated coverage on Novartis AG
- Novartis AG downgraded by Deutsche Bank